| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
|
GATHER1 [A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration] |
Total: 286 |
Iveric Bio NCT02686658 |
Primary completion: September 2019 Study completion: April 2020 |
Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: A randomized pivotal phase 2/3 trial. Ophthalmology. 2021;128:576-586. doi.org/10.1016/j.ophtha.2020.08.027 |
 Jaffe_Fig 1 |